SciBX
Science-Business eXchange

THE DISTILLERY

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Breast cancer early onset (BRCA) profile for predicting chemotherapy responsiveness and patient outcome in epithelial ovarian cancer	A study in humans suggests that a microarray gene expression profile resembling that seen in cases associated with *BRCA* mutations could help predict chemotherapy responsiveness and outcomes in epithelial ovarian cancer. Subjects having ovarian cancer with a BRCA-like profile had higher disease-free and overall survival than did those with a non-BRCA-like profile (p=0.013 and p=0.006, respectively). In 80% of subjects, the BRCA-like profile accurately predicted responsiveness to platinum chemotherapy. Next steps include studying the mechanisms responsible for the association between the BRCA-like profile and response to chemotherapy.	Patent and licensing status unavailable	Konstantinopoulos, P.A. *et al. J. Clin. Oncol.*; published online June 14, 2010; doi:10.1200/JCO.2009.27.5719 **Contact:** Stephen A. Cannistra, Beth Israel Deaconess Medical Center, Boston, Mass. e-mail: scannist@bidmc.harvard.edu

SciBX 3(26); doi:10.1038/scibx.2010.811
Published online July 1, 2010